PTC Therapeutics, Inc. announces it has priced a convertible notes offering intended to refinance its existing 2026 convertible notes. The company previously said the proposed transaction would be subject to market conditions and would be used to repurchase or repay the 2026 notes prior to or at maturity. In the priced offering, PTC Therapeutics says the proceeds will be utilized for that refinancing purpose.
According to the company’s announcement, the offering is structured with 0% interest and a conversion price of $107.48. The conversion price is described as a 40% premium over the closing price on June 15, 2026. The PR Newswire release also indicates the transaction includes a common stock buyback component.
Seeking Alpha coverage aligns with the general details that PTC Therapeutics prices convertible notes for refinancing. No additional financial terms beyond those disclosed in the press releases are provided in the supplied summaries. The announcements indicate the refinancing is designed to replace the company’s 2026 convertible notes using the newly issued notes proceeds.
